Welcome to the e-CCO Library!

search
Search by: 
Year: Category:
DOP56: has been withdrawn
Year: 2021
Source: ECCO'21 Virtual
Created: Wednesday, 2 June 2021, 4:12 PM
DOP56: Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Reinisch, W.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Magro, F.(4);Pollack, P.(3);Feagan, B.G.(5);Harpaz, N.(6);Pai, R.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP56: Long-term disease progression and resective surgery rates in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gonczi, L.(1);Lakatos, L.(2)*;Golovics, P.A.(3);Pandur, T.(4);David, G.(2);Erdélyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(5);
Created: Friday, 14 July 2023, 10:43 AM
DOP56: Long-term disease progression and resective surgery rates in Crohn’s disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Péter Laszlo Lakatos
Created: Friday, 14 July 2023, 2:22 PM
DOP56: Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe Ulcerative Colitis: Results from the UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: William Sandborn
Created: Tuesday, 23 June 2020, 5:40 PM
DOP56: Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe Ulcerative Colitis: Results from the UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: William Sandborn
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N.A. Cohen1,2, N. Plevris3, U. Kopylov2,4, A. Grinman2,4, B. Ungar1,2, H. Yanai2,5, H. Leibovitzh2,5, N. Fliss1,2, A. Hirsch1,2, E. Ritter1,2, Y. Ron1,2, A. Bar-Gil Shitrit6,7, E. Goldin6,7, I. Dotan2,5, S. Ben-Horin2,4, C. Lees3,8, N. Maharshak1,2

Created: Thursday, 30 January 2020, 10:12 AM
DOP57: Cystic fibrosis risk variants confer a protective effect against Inflammatory Bowel Disease in large-scale exome sequencing analysis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Sazonovs, Aleksejs
Created: Tuesday, 30 April 2024, 5:03 PM
DOP57: Development and validation of a convolutional neural network for the automatic detection of enteric ulcers and erosions in capsule endoscopy: A multicentric study
Year: 2022
Source: ECCO'22
Authors: Afonso , J.(1);Mascarenhas , M.(1);Ribeiro , T.(1);Cardoso , P.(1);Gonçalves , R.(1);Ferreira , J.(2);Andrade , A.P.(1);Mascarenhas Saraiva , M.(3);Cardoso , H.(1);Macedo , G.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP57: GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Heidi Soegaard Christensen
Created: Friday, 14 July 2023, 2:22 PM
DOP57: GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Christensen, H.S.(1)*;Andersen, D.(2);Jess, T.(2);Allin, K.H.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST UC
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Christian Maaser
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Mucosal healing, Ultrasound, Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Real world data, Mucosal healing
Files: 1
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Maaser*1, F. Petersen1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, D. Lang4, T. Kucharzik1

Created: Friday, 22 February 2019, 9:41 AM
DOP57: Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Maruszczak, M.(1);Genenz, K.(2);Turkstra, E.(3);Fenu, E.(2);Hantsbarger, G.(4);Gilaberte, I.(5);Karki, C.(6);Panes, J.(7)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control study
Year: 2020
Source: ECCO'20 Vienna
Authors: Nathaniel Aviv Cohen
Created: Tuesday, 23 June 2020, 5:40 PM
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control study
Year: 2020
Source: ECCO'20 Vienna
Authors: Nathaniel Aviv Cohen
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V.B. Biemans1, J.A.M. Sleutjes2, A.C. de Vries2, A.G. Bodelier3, G. Dijkstra4, B. Oldenburg5, M. Löwenberg6, A.A. van Bodegraven7, A.E. van der Meulen-de Jong8, N.K. de Boer9, N. Srivastava10, R.L. West11, T. Römkens12, C.S. Horjus Talabur Horje13, J.M. Jansen14, J. Hoekstra3, R.K. Weersma4, F.D. van Schaik5, F. Hoentjen1, M.J. Pierik15, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 30 January 2020, 10:12 AM
DOP58: An artificial intelligence–driven scoring system to measure histological disease activity in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Adsul, S.(2);Dehmeshki, J.(3);Kubassova, O.(3);
Created: Friday, 11 February 2022, 3:52 PM
DOP58: Human Leukocyte Antigen drives methylation signatures in primary sclerosing cholangitis but not in IgG4-related sclerosing cholangitis.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Motta, Rodrigo
Created: Tuesday, 30 April 2024, 5:03 PM
DOP58: IDeaL – a multi-center prospective Infliximab Dose to Level pharmacokinetic study during induction in pediatric Crohn’s disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Geraldine H. Huynh
Created: Tuesday, 28 May 2019, 3:32 PM
Anti TNF drug levels, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Therapeutic drug monitoring, Infliximab, Pharmacokinetics, Paediatric, Investigator-led
Files: 1